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1. Literature Review 
 
1.1 Calcium Oxalate stones 
Urolithiasis is a general term referring to the causes and effects of stones anywhere in the 
urinary tract. Urolithiasis should not be viewed conceptually as a single disease with a 
single cause but rather as a sequel of multiple interacting underlying abnormalities. Thus, 
the syndrome of urolithiasis may be defined as the occurrence of familial, congenital, or 
acquired pathophysiological factors that, in combination, progressively increase the risk 
of precipitation of excretory metabolites in urine to form stones (i.e. uroliths). Several 
types of stones can be formed, and are classified based on their mineral components (1, 
4).  
The Minnesota Urolith Center has been analyzing uroliths for over 30 years and it has 
observed a dramatic increase in the prevalence of dogs and cats with calcium oxalate 
(CaOx) uroliths worldwide (1, 2, 3, 4, 5). They represent 40 to 45% of the samples 
analyzed in both species (2).  In addition, over 90% of nephroliths and ureteroliths 
(kidney and ureter stones, respectively) are composed of calcium oxalate (12, 13). 
Urolithiasis incidence and composition have also changed in humans over the past five 
decades, with a substantial increase in the incidence of CaOx stones as well (6, 7). It’s 
estimated that 10% of people will develop nephrolithiasis, and 70% of those will 
experience recurrences. Among them 80% of stones are calcium based, and 80% of those 
are calcium oxalate stone formers (11). 
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The driving force leading to urolith development is the supersaturation of urine with 
calculogenic substances. When calcium and oxalate reach supersaturation in the urine, 
calcium oxalate crystals spontaneously precipitate, crystallization takes place and crystals 
initiate aggregate formation (8, 9).  
Epidemiologic studies support the hypothesis that in recent decades diets designed to 
minimize estruvite (magnesium ammonium phosphate – MAF) urolith formation may 
have increased the occurrence of CaOx stones. Diet-mediated urine acidification 
enhances the solubility of MAF crystals in urine, but promotes calcium oxalate 
crystalluria by inducing hypercalciuria (4). Increased excretion of calcium in the urine 
appears to be an important contributor to CaOx stone formation. However, it is not 
believed to be a significant risk factor in humans, since 24-hour urinary excretion of 
calcium is normal in some CaOx urolith formers and, in some nonurolith-forming 
humans, 24-hour urinary excretion of calcium is elevated (19). However, studies have 
shown that CaOx stone-forming dogs do excrete significantly higher levels of calcium
 
than healthy non-stone forming dogs (20, 21).  
Calcium homeostasis is achieved by a complex set of actions of parathyroid hormone 
(PTH) and vitamin D on intestines, kidneys and bones. Therefore, increased calcium 
levels can result from excessive absorption by intestines, decreased renal reabsorption 
and skeletal mobilization of calcium (9). The exact role of calcium in CaOx urolith 
formation in dogs and cats remains unclear, although combinations of familial, congenital 
and acquired pathophysiological abnormalities, such as primary hyperparathyroidism, 
vitamin D intoxication, osteolytic neoplasia and hyperthyroidism contribute to CaOx 
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urolithiasis in small animals (22, 23). 
Nonetheless, hyperoxaluria due to increasing urine CaOx saturation is an important risk 
factor for calcium oxalate urolith formation. In humans, a vast number of epidemiologic 
studies confirmed that a small increase of oxalate concentration in the urine significantly 
enhanced the risk of CaOx urolith formation (23). 
The precise cascade of events leading to CaOx stone formation is unknown. As a result, 
medical therapy to dissolve CaOx uroliths is currently unavailable, no treatment has been 
shown to be completely eﬀective, contemporary therapies do not provide a long term 
solution and uroliths are commonly associated with lower urinary tract discomfort and 
potential life-threatening urethral obstruction. In addition, they are a common cause for 
ureteral obstruction and kidney failure.  Although in concept surgical removal of upper 
urinary tract uroliths may restore kidney function, ureteral surgery has been associated 
with significant risks. In a study of 101 cats with calcium oxalate ureteroliths, the 
postoperative complication rate was 31% and the mortality rate was 18%. Chronic kidney 
failure present at the time of diagnosis remained following ureterolith removal (10).  
Currently, voiding or retrograde urohydropropulsion, lithotripsy and surgery are the only 
options for removal of active CaOx uroliths (14). Although not common, CaOx 
urolithiasis associated with bacterial urinary tract infection should be treated. Uroliths 
that cause urethral obstruction should be retro-pulsed into the urinary bladder. This can 
be accomplished by retrograde urohydropropulsion, whereas voiding urohydropropulsion 
may be used to retrieve uroliths that have a diameter smaller than the diameter of the 
urethral lumen, as described by Lulich et al. (24). Another nonsurgical method is 
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lithotripsy, which breaks uroliths that are later collected by cystoscopic- or fluoroscopic-
guided basket extraction of remaining fragments (9,25). Lastly, surgery can remove 
active ureteroliths and nephroliths, and nephrectomy is performed when kidneys are 
severely affected or nonfunctional (9).  
Regardless of which treatment is chosen, CaOx stones are recurrent and because of that, 
removal of uroliths should not be the end point of therapy. During a study with thirty-
three CaOx stone-forming dogs, 36% developed CaOx stones again after one year, 42% 
after two years, and 48% after three years (15). Thus, therapeutic strategies are needed to 
prevent formation and re-formation of CaOx stones. 
 
1.2 Oxalate 
Oxalic acid and/or oxalate salts are extensively present in animals, plants and microbes as 
a metabolic end product. In mammals, oxalate is generated endogenously (mainly in 
liver) from the metabolism of glycine, hydroxyproline, serine, glyoxylate, glycolate and 
ascorbate. As mammals are incapable of metabolizing it, oxalate is excreted via urine. 
Absorbed oxalate from the intestine also is excreted through the urine (29, 31).  
It is not clear if the majority of urinary oxalate is derived from endogenous metabolic 
pathways or from the diet, although increased urinary oxalate appears to be sustained by 
an increased dietary load of oxalate and increased intestinal absorption. It was 
demonstrated that urinary oxalate concentration gradually declines in individuals that 
consume an oxalate-free diet and also that modifications in the diet can alter urine 
composition in dogs and humans (32, 33). 
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Dietary oxalate can be catabolized in mammalian species only through the action of 
oxalate-degrading bacteria. A popular example is the strict anaerobe, Oxalobacter 
formigenes, which colonizes the intestines of dogs, cats, rats and humans (26, 27, 28, 29, 
30). Studies in rats showed that the intestinal microflora, in particular Oxalobacter 
formigenes, utilize oxalate in the gut, limiting its intestinal absorption and subsequent 
urinary excretion (16). In humans, colonization of the intestine with this bacterium 
showed reduction of urinary oxalate as well as plasma oxalate levels (17). Additionally, 
the presence of O. formigenes in the gut was associated with a 70% reduction in the risk 
for being a recurrent calcium oxalate stone former (18).  
To summarize, enteric microbes metabolize oxalate and limit enteric oxalate absorption. 
It has been speculated that 50% to 80% of dietary oxalate is degraded by oxalate 
metabolizing bacteria in the gut (34).  
 
1.2.1 Oxalate-degrading enzymes 
There are three types of enzymes known to degrade oxalate in nature; oxalate oxidase 
(OxOx), expressed primarily in plants, although also isolated from the fungus 
Ceriporiopsis subvermispora (35, 36); oxalate decarboxylase (OXDC) and oxalyl-CoA 
decarboxylase (OXC), both of which are expressed in bacteria and fungal species (36).  
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Figure 1. Enzymes that catalyze the degradation of oxalate (adapted from Svedruzic (36)). 
 
 
1.2.2 Oxalate Oxidase (OxOx) 
OxOx is found in a wide variety of plants and converts oxalate to CO2 and H2O2 (Figure 
1). Its expression confers fungal disease resistance in crop plants, including Amaranthus 
leaves, beet stems and leaves, sorghum leaves, maize, oats, rice and rye (38), with the 
barley enzyme being the best described in plants (37) and Ceriporiopsis subvermispora in 
fungi (35). 
Native OxOx is a glycoprotein that crystallizes as a hexamer, the biologically active form 
of the enzyme. It is hypothesized that the quaternary structure is responsible for the 
resistance of OxOx to degradation by heat and proteases. Each monomer of OxOx 
contains manganese (Mn), which supports the observation that specific enzyme activity is 
correlated with increasing Mn content, where oxalate binds on the catalytic site of the 
protein (35, 36, 37). Native OxOx exhibits an optimal enzyme activity at pH 4.0 (37).  
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The protein was shown to have a 65.5-kDa subunits (400-kDa hexamer) with a Km for 
oxalate of 0.1mM and a Kcat of 88s-1. The enzyme is located in membrane-bound vesicles 
that are exported to the periplasmic and extracellular space (39).  
Oxalate oxidases belong to the cupin protein superfamily (35), which is divided into two 
broad groups: the monocupins (including OxOx and germin-like proteins) and the 
bicupins (including OXDC), which are twice the size of monocupins. However, 
sequences of OxOx from C. subvermispora resemble those of bacterial bicupin OXDC 
instead of the plant monocupin OxOx (known as germin). For that reason, fungal OxOx 
is a new class of OxOx (35, 36). 
 
1.2.3 Oxalate Decarboxylase (OXDC) 
OXDC catabolizes oxalate directly to formate and CO2 (Figure 1). It was first described 
50 years ago in the basidiomycete fungus Collybia (Flammulina) velutipes (36, 40). 
Subsequent studies have reported OXDC in other fungi, such as Aspergillus niger, 
Sclerotinia sclerotiorum, Agaricus bisporus, and in at least one bacterium, Bacillus 
subtilis. While the expression of OXDC in fungi is induced by oxalate, it is also induced 
in the bacterium by acidic pH (e.g. 5.0) (40,41).  
All OXDCs are bicupins that require Mn as a co-factor, bound to both cupin domains, 
which is the same Mn-binding sequence motif that is present in OxOx. However, OXDC 
also requires dioxygen in the catalytic mechanism, being inactive when mixed with 
substrate (oxalate) under anaerobic conditions (36, 41, 42).  
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Fungal OXDC can be both an intracellular and extracellular enzyme, being secreted by 
hyphal cells. In the case of B. subtilis, the protein is exclusively a cytosolic enzyme (36, 
41). The protein from B. subtilis has a Km of 15 mM and a Kcat of 54 s-1 whereas in F. 
velutipes the Km is 4.5 mM and has a Kcat of 166 µmol min-1 mg-1, i.e. lower than B. 
subtilis (42). 
Current models of enzyme evolution suggest that OXDC might have evolved from OxOx 
by gene duplication. OXDC has a quaternary structure composed of two homotrimers and 
each trimer resembles the OxOx hexamer (36).  
 
1.2.4 Oxalyl-CoA Decarboxylase (OXC) 
Oxalate degradation in bacteria is first mediated by oxalyl-CoA decarboxylase (OXC), 
which converts oxalyl-CoA into formyl-CoA and CO2 (Figure 1). In order to complete 
oxalate metabolism by OXC, the activity of formyl CoA transferase (FRC) is required, 
since FRC transfers CoA from formyl CoA to oxalate and forms Oxalyl CoA. Both are 
essential to metabolize oxalate to formate and CO2, along with a membrane-bound, 
formate/oxalate antiporter (encoded by the oxlT gene), importing oxalate into the cell and 
exporting formate. OXC is a thiamin-dependent enzyme that is constitutively expressed 
in Oxalobacter formigenes, an obligate anaerobe that solely depends on oxalate for ATP 
synthesis (36, 43).  
Although the genes coding for OXC, FRC and OxlT play a role in the same function 
(oxalate metabolism), they are located in different operons, driven by independent 
promoters and terminator sequences (44). Therefore, as oxalyl-CoA decarboxylase uses a 
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very different and complex mechanism to metabolize oxalate, it will not be addressed 
further.  
 
1.2.5 Heterologous expression of oxalate-degrading enzymes 
Oxalate secretion by fungi provides advantages for their growth and is associated with 
plant pathogenesis. Sclerotinia sclerotiorum is an ascomycete that causes diseases in 
more than 400 plant species, including economically important crops such as tomato, 
soybean and lettuce. Transgenic lettuce lines containing the OXDC gene from 
Flammulina velutipes were produced, in order to confer resistance to these plants, by 
degrading the toxic oxalic acid (45).  
Oxalate oxidase (OxOx) from Ceriporiopsis subvermispora was previously cloned and 
sequenced, and OXDC from B. subtilis was cloned into a recombinant Lactobacillus 
plantarum to degrade oxalate in vitro for future therapy against hyperoxaluria (46). In 
this study, L. plantarum constitutively overexpressed B. subtilis OXDC and was able to 
degrade more than 90% of the oxalate in vitro compared to 15% by the wild-type 
bacterium. (46). Additionally, our lab has engineered a probiotic strain, E. coli Nissle 
1917 (EcN), to express heterologous B. subtilis oxalate decarboxylase capable of 
metabolizing oxalate in vitro (J. Gnandarajah, PhD thesis, University of Minnesota, 
2007). In regards to the oxalate-degrading enzymes of Oxalobacter formigenes, stable 
expression of OXC and FRC genes in human embryo kidney 293 cells was reported, but 
there was no significant difference in oxalate degradation between samples and controls 
(47).  
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Finally, there are no published data on co-expression of all three genes (OXC, FRC, 
OxlT) in a heterologous host bacterium, nor any oxalate decarboxylase enzyme 
expression in a eukaryotic system.   
 
1.3 Gene therapy 
Gene therapy can be defined as a molecular-based tool used to transfer a gene that 
encodes a protein to functionally replace a defective or absent homolog in order to 
produce long-term expression. Gene therapy is becoming the medicine of the near future 
and there are currently several successful examples, as in the case of cystic fibrosis in 
humans and blinding retinal disease in dogs (48, 49).  
 
Identifying a potential candidate for this approach in regards to preventing calcium 
oxalate stones, both in small animals and humans, is the first step to develop an effective 
therapy for this disease.  
This study is expected to trigger further research focused on determining methods of gene 
transfer, identifying effective and safe delivery routes, prolonging transgene expression, 
and overcoming vector-mediated innate immune responses. 
 
1.4 General hypothesis and objectives 
Our long-term research goal is to develop safe and effective therapies to prevent stone 
recurrence in humans and animals. Here, our principal objective is to evaluate the 
feasibility of reducing oxalate concentrations by ectopic expression of oxalate-degrading 
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enzymes in a simple cell culture model of the kidney. 
Our hypothesis is that enzyme expression and secretion from feline kidney cells 
(Crandall-Rees Feline Kidney, CFRK, cell line) will result in oxalate elimination from 
culture media. Efficient oxalate-degrading enzymes are not found in the mammalian 
genome, so bacterial and fungal enzymes were evaluated. 
Objective 1. To clone different oxalate-degrading enzymes, since they might vary in 
efficacy of expression; Different sources of microorganisms able to degrade oxalate were 
used: Bacillus subtilis (OXDC), Ceriporiopsis subvermispora (OxOx) and Flammulina 
velutipes (OXDC). 
Objective 2. To evaluate plasmid transfection into a feline kidney cell line, in order to 
characterize a transfection method optimized for this cell line. 
Objective 3. To assess oxalate-degrading activity of transfected cells, by measuring 
oxalate and formate content in the media. 
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2.1 Introduction 
The target oxalate degrading enzymes are monomeric, soluble proteins expressed in 
cytoplasm or secreted from the cell. Thus, they are expected to assume native, functional 
conformations that retain enzymatic activity in the extracellular environment of kidney 
cells. The proposed plan uses bacterial and fungal enzymes that are naturally secreted 
from host species maintained by University of Minnesota faculty, Dr. David Mc Laughlin 
and Dr. Robert Blanchette (Departments of Plant Biology and Plant Pathology, 
respectively).  
 
2.2 Materials and Methods 
In order to clone different oxalate-degrading enzymes, since they might vary in efficacy 
of expression, different sources of microorganisms (bacteria and fungi) able to degrade 
oxalate were used: Bacillus subtilis (OXDC), Ceriporiopsis subvermispora (OxOx) and 
Flammulina velutipes (OXDC) (Table 1).  
Table 1. Oxalate-degrading enzymes’ molecular features. 
Species Enzyme Secreted Signal sequence 
Bacillus subtilis OXDC No No 
Flammulina 
velutipes OXDC Yes Yes 
Ceriporiopsis 
subvermispora OxOx Yes Yes 
 
   15 
 
Vegetative cultures of both fungi growing on agar in Petri plates were obtained from the 
Departments of Plant Biology and Plant Pathology (University of Minnesota). They were 
further grown in 2% malt agar stored in 18°C to 20°C for three weeks in order to increase 
the amount of mycelium for RNA extraction. Genomic DNA from B. subtilis was 
obtained from prior studies in our laboratory. 
RNA from 15 mg of mycelium of each F. velutipes and C. subvermispora were extracted 
using the RNeasy Plant Mini Kit (Qiagen®) and cDNA synthesis was performed using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems®).  
Open reading frames (ORF) sequences were amplified by PCR (High Fidelity 
Polymerase - Clontech®) using primers designed based on sequences in GenBank. 
Amplification was performed in a GeneAmp PCR system 2400 (Perkin Elmer) with 
activation at 98°C for 5 minutes, followed by 35 cycles of denaturation at 98°C for 10 
seconds, annealing at 55°C for 20 seconds and extension at 72°C for 1 minute and final 
elongation at 72°C for 5 minutes. Amplicons were resolved by agarose gel 
electrophoresis and visualized by ethidium bromide staining. Target DNA sequences 
were purified using QIAquick PCR Purification kit (Qiagen®) and recombinant plasmids 
were generated using the Infusion HD Cloning kit (Clontech®), which fuses DNA 
fragments and linearized vectors by recognizing a 15 bp overlap at their ends (Figure 2).  
Two different mammalian expression vectors were used: pSG9M (52) and pSecTag by 
Invitrogen® (Figure 3). Among our genes of interest, fungal species contain a signal 
peptide (SP) sequence encoded within the gene, while the B. subtilis enzyme does not. 
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The pSG9M plasmid does not contain a plasmid-encoded leader sequence for guiding the 
protein into the secretory pathway in the cell, while pSecTag contains an IgK signal 
sequence for protein secretion. Therefore, these recombinant plasmids were generated 
based on the presence or absence of a signal peptide sequence in the vector and in the 
ORF. 
Figure 2. Infusion cloning method (Infusion HD Cloning User Manual – www.clontech.com). 
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Figure 3. pSG9M and pSECTAG vectors.  
 
Primers were designed based on published sequences and also constructed to overlap 
15bp of target sequence and 15 bp of vector region (Table 2). 
Plasmids were transformed into E. coli XL10 Gold cells and transformants were screened 
on Luria-Bertani (LB) agar plates containing vector-specific antibiotic (ampicillin). The 
following controls were included: competent cells without plasmid growing on plates 
without antibiotic (positive control for viability), and with antibiotic (negative control for 
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endogenous resistance), transformation with intact vector (positive control for 
transformation) and a linearized vector (negative control) and plating on antibiotic-
containing plate. Clones were screened again by colony PCR and DNA from positive 
clones was sequenced. Fifteen colonies of each plate were screened for each of the 
samples. DNA fragments within the pSecTag-plasmid were amplified using primers 
targeting the vector T7 promoter (forward: TAATACGACTCACTATAGGG) and the 
BGH polyadenylation signal (reverse: TAGAAGGCACAGTCGAGG). DNA fragments 
within the pSG9M-plasmid were amplified using primers targeting the beginning and 
ending of the multiple cloning site region (MCS), as follows, forward: 
CGGTTACCAACATGGAACAA and reverse:  CGAGGAAGCGGAAGAGTCTA 
(Figure 3).  
Each positive colony was further grown in 5 ml of LB and ampicillin for 8h at 37°C with 
vigorous shaking (around 300 rpm). Then, 100 ul of starter culture was inoculated into 
100 ml of LB and ampicillin at 37°C for 12 to 16h with vigorous shaking. Cells were 
then harvested by centrifugation and the EndoFree Plasmid Kit (Qiagen®) was used to 
purify recombinant plasmids from E. coli cells, in order to remove bacterial endotoxins 
that are released during the lysis step and that can further influence transfection of DNA 
into cultured cells. 
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Table 2. List of primers used for amplification of target sequences. 
Host / Enzyme / Vector Sequence 
B. subtilis / OXDC / pSG9M / Forward CCATGAATTCTAGTGGAAATGACATTCCGCAGCCAAT 
B. subtilis / OXDC / pSG9M / Reverse GGATCGGGCCCCCCCTCTTTACTGCATTTCTTTTTCA 
B. subtilis / OXDC / pSecTag / F TTGGTACCGAGCTCGAATGACATTCCGCAGCCAAT 
B. subtilis / OXDC / pSecTag / R TTGTTCGGGCCCTCCTTTACTGCATTTCTTTTTCACT 
F. velutipes / OXDC / pSG9M / F CCATGAATTCTAGTGGATTCAACAACTTCCAACGTCT 
F. velutipes / OXDC / pSG9M / R GGATCGGGCCCCCCCTCGTTCACAGGACCAACAACA 
F. velutipes / OXDC / pSecTag / F TTGGTACCGAGCTCG TTCAACAACTTCCAACGTCTGC 
F. velutipes / OXDC / pSecTag / R TTGTTCGGGCCCTCCGTTCACAGGACCAACAACAGTC 
C. subvermispora / OxOx / pSG9M / F CCATGAATTCTAGTGGAAACGAGAAGCTCGTTT 
C. subvermispora / OxOx / pSG9M / R GGATCGGGCCCCCCCTCATCTGAGGCGACAACGAAT 
C. subvermispora/OxOx/pSecTag / F TTGGTACCGAGCTCGAACGAGAAGCTCGTT 
C. subvermispora/OxOx/pSecTag / R TTGTTCGGGCCCTCCATCTGAGGCGACAAC 
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2.3 Results 
ORFs from all organisms were successfully amplified (Figure 4), and confirmed to be 
specific by sequencing.  
 
Figure 4. PCR analysis of ORFs. PCR products; Lane 1: OXDC (1341bp) F. velutipes; Lane 2: OXDC 
(1281bp) F. velutipes (signal peptide – SP not included); Lane 4: OxOx (1418bp) C. subvermispora; Lane 
5: OxOx (1358bp) C. subvermispora (no SP); Lane 7: OXDC (1158bp) B. subtilis. 
 
 
PCR was performed in 15 colonies from each recombinant plasmid in order to check if 
the genes were correctly inserted within the vectors. All positive colonies were confirmed 
by PCR (Figure 5 and 6) and sequencing, except the clones related to C. subvermispora 
(OxOx), which resulted only in a few colonies, that did not contain the target ORF. 
 
 
 
 
 
 
 
3 2 1.5 1.2 1 
Kb Lane	  1 Lane	  2 Lane	  4 Lane	  5 Lane	  7 
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Figure 5. Colony PCR of OXDC from B. subtilis (lanes 1 and 7 – 1158 bp) and F. velutipes (lanes 2, 3, 
4, 8, 9 and 10 – 1341 bp) within pSG9M vector (2log ladder). 
 
 
Figure 6. Colony PCR of OXDC from B. subtilis (1446 bp) within pSecTag vector - all lanes. 
 
 
Successful recombinant plasmids were purified using the EndoFree Plasmid Purification 
Kit (Qiagen®) and samples were analyzed by agarose gel electrophoresis (Figure 7). 
 
 
 
 
 
1 1.2 
1.5 2 
Kb 1 2 3 4 7 8 9 10 
Kb 
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1 
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Figure 7. Gel electrophoresis of endotoxin-free plasmids (lane 1: pSecTag pure - 5.1kb, lane 2: pSecTag 
and OXDC from B. subtilis – 6.2kb, lane 3: pSecTag and OXDC from F. velutipes – 6.4kb, lane 4: pSG9M 
and OXDC from B. subtilis – 5.1kb, lane 5: pSG9M and OXDC from F. velutipes – 5.3kb).  
 
 
2.4 Discussion 
Enzymes able to degrade oxalate have potential applications, including production of 
transgenic plants that resist fungal disease, bioremediation, and treatment of 
hyperoxaluria. Excess of oxalic acid is toxic for all organisms and mammals are not able 
to degrade oxalate.  
In our study, eukaryotic expression vectors pSecTag and pSG9M were used to clone 
OxOx and OXDC from bacteria and fungi. Both vectors contained a CMV 
(Cytomegalovirus) constitutive mammalian promoter for high-level expression and a c-
myc epitope for detection with an anti-myc antibody. Secreted expression is the key 
function of pSecTag, since it also contains a signal peptide sequence derived from the 
mouse Ig kappa-chain mRNA for efficient secretion of recombinant proteins.  
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The well-known oxalate-degrading enzyme of Oxalobacter formigenes consists of three 
subunits, of which the catalytic component is a multiple membrane spanning protein, and 
exceptionally difficult to express in an active form (43, 44). Therefore, this work was 
focused on expressing oxalate-degrading proteins from other sources that might be more 
suitable for protein engineering and expression. 
OXDC from F. velutipes has been successfully expressed in lettuce, tobacco and tomato, 
conferring resistance against the fungal infection of Sclerotinia sclerotiorum, a 
microorganism that produces copious amounts of oxalic acid (45). Similarly, OXDC 
from B. subtilis, was constitutively expressed in Lactobacillus plantarum, to degrade 
oxalate under in vitro conditions (46). Additionally, oxalate oxidase from barley 
(Hordeum vulgare) were cloned and tested in an Escherichia coli expression system, 
although the protein was not active (37). On the other hand, substantial amounts of active 
OxOx were obtained by expression in Pichia pastoris (53).  
In summary, we have identified and isolated genes already known to be associated with 
oxalate degradation. They were cloned and recombinant plasmids were constructed using 
two different mammalian expression vectors, which were later amplified by bacteria in 
order to make large quantities of it. However, recombinant oxalate oxidase plasmid from 
C. subvermispora was either not taken by bacteria or unsuccessfully cloned, since colony 
PCR did not show presence of the gene, leaving oxalate decarboxylases from F. velutipes 
and B subtilis to be transfected and expressed by mammalian cells, in order to identify the 
best gene candidate for future gene therapy techniques.  
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Chapter 3 – Transfection optimization into Crandall Rees Feline Kidney (CRFK) 
cell line 
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3.1 Introduction 
OXDC is a prokaryotic gene expressed in fungal and bacterial species and it is uncertain 
if OXDC can be expressed in eukaryotes. We constructed an eukaryotic expression 
system using CRKF cells, in order to check if this cell line can gain the capacity of 
oxalate metabolism by the heterologous expression of OXDC, becoming a promising new 
therapy for treating and preventing hyperoxaluria in small animals by targeting kidney-
specific cells. In order to evaluate plasmid transfection and to characterize the best 
method optimized for this cell line, plasmids were purified and transfected into CRFK by 
different methods. 
 
3.2 Materials and Methods 
CRFK cells were maintained in Dulbecco’s Modified Eagle Medium (Gibco® DMEM) 
supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (100 µg 
ml−1 and 100 U ml−1, respectively) at 37°C in 5% CO2.  
Various transfection techniques, including lipofection (Lipofectamine 2000 – Life 
Technologies®), cationic polymers (Xfect Transfect Reagent – Clontech®) and 
nucleofection (Lonza®) were compared. Experiments used transiently transfected cells 
and all plates contained positive and negative controls. Positive control was used with a 
GFP-expressing plasmid and examination by fluorescence microscopy, and bisbenzimide 
staining of nuclei to determine transfection efficiency. The negative control was 
untransfected cells.  
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Transfected cells were detected by immunofluorescence (IF). Cells were fixed in 4% 
methanol-free paraformaldehyde in PBS for 20 min. Cells were rinsed 3x with PBS and 
permeabilized with 0.1% Triton X-100 for 10 min. Cells were then blocked with 3% BSA 
for an hour at room temperature. Primary antibody (mouse anti c-myc monoclonal 
antibody from Life Technologies®) was diluted 1:1000 and incubated with cells for an 
hour at 370C. After washing cells twice with PBST, Alexa Fluor 488 goat anti mouse IgG 
(Life Technologies®) was diluted 1:1000 in PBST and added with cells for 45 minutes at 
370C protected from light. Lastly, staining of nuclei was performed by diluting 1:1000 
bisbenzimide and incubating cells for 20 minutes at room temperature also protected 
from light. At this point, cells were washed with PBST and kept at 4°C until further 
analysis. 
Cells were first transfected using the Xfect polymer according to the manufacturer’s 
instructions. In this method, the negatively charged DNA binds to the polymer and the 
complex is taken up by the cell via endocytosis. 10,000 cells per well in a 24-well plate 
were transfected, and analysis was performed 48h after transfection.  Several 
optimization steps were performed, including the amount of transfected DNA (0.5 to 2 
ug), time of analysis (24h, 36h and 48h) and concentration of transfection polymer (0.1 to 
0.6 ul). 
The second method used was lipofection with Lipofectamine 2000(Life Technologies®), 
in which genetic material is injected into the cell by liposomes, which are phospholipid 
vesicles that can easily merge with the phospholipid bilayer of the cell membrane. 
Lipofection generally uses a positively charged (cationic) lipid to form an aggregate with 
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the negatively charged (anionic) genetic material. As with the Xfect reagent, this method 
was also optimized by adjusting concentrations of transfected DNA (0.5 to 5 ug), 
Lipofectamine reagent (2 to 5 ul) and time of analysis (24h, 36h and 48h). It was 
performed following manufacturer’s instructions, using 10,000 cells per well in a 24-well 
plate. 
The last method evaluated was nucleofection with a Nucleofector 2b device (Lonza®) 
and the solution V, as recommended by the manufacturer for this cell line. This tool uses 
a combination of electrical parameters, generated by the Nucleofector, that transfer the 
DNA directly into the cell nucleus and cytoplasm. 10,000 cells per well in a 24-well plate 
were used and several nucleofection programs were evaluated, all were reported as 
successful and had given satisfactory transfection efficiency rates, according to the 
manufacturer’s webpage. Programs tested were T-020, T-019, V-013 and V-017; plasmid 
concentrations were 2, 5, 10 and 20 ug.  
Transfection efficiency was calculated based on the total number of transfected cells 
(green fluorescence) divided by the total number of cells (nuclei staining).  
 
ELISA protocol 
Protein in the cell-free supernatant and lysate were detected by a “sandwich” enzyme-
linked immunosorbent assay (ELISA), developed specifically to eliminate a need to 
purify the protein before measurement, simplifying the assay, and increasing the 
specificity and the sensitivity of the assay.  
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Briefly, wells of a 96-well plate were coated with a rabbit anti-myc antibody (Sigma 
Aldrich®) diluted 1:1000, in duplicate wells, 100 ul per well, and incubated 24h at 4°C. 
Plates were washed with PBST, pH 7.4, at room temperature in an ELx405 Microplate 
Washer® (Bio-Tek Instrument Inc. Winooski, VT). The plates are then washed 3X and 
blotted to remove excess liquid. 300 ul/well of Blocking Buffer (5% non-fat dry milk in 
PBST, pH 9.4) was added to each well and the plates were allowed to stand for 2h at 
room temperature. Plates were washed again and 100 ul of cell culture supernatant from 
CRFK cells transfected with oxalate degrading enzymes, grown in OptiMEM serum free 
media, was added and incubated for 1h at room temperature. Plates were washed again 
and secondary antibody was added (mouse anti-his monoclonal antibody, Novex®) 
diluted 1:1000 in NFDM, pH 7.4, was added to each well then incubated for 1h at room 
temperature. Plates were washed one more time and detection antibody was added (anti 
mouse IgG HRP conjugate (Bethyl®) diluted 1:10,000 in 5% NFDM in PBST, pH 7.4, 
and mixed thoroughly. 100 ul was added to each well and incubated for 1h at room 
temperature. Plates were washed for the last time and 100 ul of enzyme substrate was 
added, allowed to develop a blue color for exactly 15 minutes at room temperature, and 
finally 100 ul of 1M phosphoric acid stop solution was added. Plates were read at 450 nm 
on a Thermo Max Microplate Reader (Molecular Devices®, Sunnyvale, CA). 
A positive control myc-tagged protein, the porcine corcovirus 2 replicase, was included 
in all plates at concentrations ranging from 5 to a 100 ng per 100 ul, along with 
untransfected supernatants and uncoated wells (negative controls).   
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Immunoblot 
The total proteins of transfected cells were subjected to a 4-20% SDS-PAGE gel 
electrophoresis for 1 hour and then electro-transferred to a PVDF membrane (Millipore-
FL®). The membrane was blocked with Odyssey Blocking Buffer (Licor®) for 1 hour at 
room temperature and then washed 3x with PBST. Incubation with mouse anti-myc 
monoclonal antibody (Life Technologies®) diluted 1:5000 with a labeling IRDye 680RD 
goat anti-mouse IgG diluted 1:1000, 0.1% Tween20 and 0.01% SDS was performed for 1 
hour, shaking, at room temperature. Membrane was scanned on an Odyssey machine 
using a detection channel of 700 nm.  
A positive control myc-tagged porcine circovirus 2 replicase was included, along with 
untransfected supernatants and lysates (negative controls). 
 
3.3 Results 
Crandall Rees feline kidney cells transfected with cationic polymers (Xfect reagent®) did 
not show satisfactory results. Transfection efficiency ranged between 5 to 20% for the 
GFP-containing plasmid (positive control) and less than 5% for samples (Figure 8). The 
results were obtained when added the maximum amount of plasmid DNA recommended 
(2 ug), analysis at 48 hours and using a concentration 0.6 ul of transfection polymer. 
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Figure 8. Transfected cells identified by green fluorescence (GFP-containing plasmid). 
 
Lipofection also was not successful, showing less than 2% of transfection efficiency 
(Figure 9). However, when cells were transfected by nucleofection, transfection rates 
reached up to 95%. In this last method, efficiency increased as the concentration of 
plasmid transfected increased. Different amounts of plasmid were tested: 2, 5, 10 and 20 
ug, being 20ug the optimal plasmid concentration (Figure 10). Among 4 nucleofection 
programs recommended by the manufacturer’s website for this cell line, T-020 showed 
the highest transfection efficiency. Samples and controls were duplicates, 3 fields per 
well were analyzed for each and had their transfection efficiency averaged.   
Figure 9. Lipofectamine-transfected GFP-containing plasmid CRFK cells. 
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Figure 10. CRFK cells transfected by nucleofection. pSecTag_BS (OXDC from B. subtilis), 
pSecTag_FV (OXDC from F. velutipes), pSG9M_BS (OXDC from B. subtilis), pSG9M_FV (OXDC from 
F. velutipes) – Program T-020. 
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ELISA results showed high amounts of protein, both intracellular and extracellular, for 
both recombinant pSecTag cells. A standard curve was made based on the positive 
control protein myc-tagged from PCV (Figures 11 and 12). 
 
Figure 11. ELISA results: standard curve based on the positive control – protein myc-tagged from 
PCV. Poly. (REP) – polynomial curve fitting;  
  
 
Figure 12. Amounts of proteins were determined by the standard curve. 
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The samples subjected to the ELISA assay, were also used to be evaluated by protein 
immunoblotting, which was performed using a mouse anti-myc monoclonal antibody. 
Supernatant and lysate total proteins of transfected cells were subjected to a 4-20% SDS-
PAGE gel electrophoresis and the results showed bands corresponding to the predicted 
size of OXDC proteins (48kDa from F. velutipes and 43kDa for B. subtilis). The 
immunoblot included a negative control (untransfected cells) and positive control 
replicase. Expression of OXDC was detected in samples transfected with recombinant 
OXDC from both F. velutipes and B. subtilis (Figure 13).  
Figure 13. Western Blot analysis. Lane 2: Protein supernatant of pSecTag_FV-transfected cells 
(OXDC); Lane 3: Cell lysate of pSecTag_FV-transfected cells (OXDC); Lane 5: Protein supernatant 
of pSecTag_BS-transfected cells (OXDC); Lane 6: Cell lysate of pSecTag_BS-transfected cells 
(OXDC); Lane 7: Protein supernatant of untransfected cells; Lane 8: Cell lysate of untransfected 
cells; Lane 9: myc-tagged protein control from PCV (REP). 
 
 
3.4 Discussion 
CRFK cells were isolated from the cortical portion of the kidneys of a 10-12 week old 
normal female domestic cat (50). There is no apparent loss of susceptibility of the cells to 
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selected viruses, not even after 200 passages, thus the cell line is extensively used in 
feline virus research (50). The experiments here used transiently transfected cells in order 
to investigate the short-term impact in protein expression. DNA was not integrated into 
host genome, and gene expression was temporary (24h to 96h).  
Positive controls were performed with a GFP-expressing plasmid and examination by 
fluorescence microscopy, and bisbenzimide staining of nuclei to determine transfection 
efficiency. Endotoxins were removed from plasmid preparations, since some cell lines 
show reduced transfection efficiencies in its presence (54).  
Transfection of CRFK cells was not previously reported, therefore multiple methods were 
evaluated. Cationic polymers (Xfect reagent®) and liposome-mediated transfection 
(Lipofectamine 2000 – Life Technologies®) did not show satisfactory transfection 
efficiency, although other kidney cell lines have been successfully transfected according 
to the manufacturer’s website. Nucleofection, a technique that uses electricity to create 
transient pores in the cellular membrane to enable uptake of DNA into the cells, was 
highly efficient, resulting in up to 90% transfection when using pSecTag constructs. 
Transfection rates increased as the amount of plasmid was increased (Figure 10), which 
resulted in the use of 20 ug of plasmid for every experiment. However, the pSG9M 
vector-based test constructs showed a maximum efficiency of 30%. Thus, pSecTag_FV 
and pSecTag_BS were selected for further characterization since they gave higher protein 
expression and secretion levels.   
A sandwich ELISA was developed to measure the amount of protein both in supernatant 
and lysate of transfected cells, by taking advantage of two antigenic epitopes (myc and 
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His tags) capable of binding to two antibodies (anti-myc and anti-His). Concentrations of 
recombinant proteins were determined by a standard curve based on a positive control 
protein (PCV2 replicase) with the same tags. Samples did not need to be purified prior to 
the assay, due to its high specificity. It was very useful for analysis of low protein 
concentrations in the presence of other cellular and serum proteins. In addition, protein 
immunoblot results also demonstrated that both recombinant OXDC proteins were being 
expressed and secreted by CRFK transfected cells. 
However, it was still uncertain whether these recombinant proteins kept their enzyme 
activity as secreted proteins in a feline kidney cell line. 
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Chapter 4 – Oxalate-degrading activity of transfected cells 
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4.1 Introduction 
In mammals, oxalate-degrading bacteria in the gut minimize the absorption of oxalate. 
Based on that, scientists have been trying to achieve a stable probiotic-colonization of 
these bacteria, although consistent reduction in urinary oxalate levels was not observed 
among different studies (55, 56). 
In our approach, oxalate-degrading enzymes would be incorporated into mammalian 
kidney cells by gene therapy, giving them capacity to degrade oxalate and to reduce the 
levels of oxaluria. In order to accomplish that, two gene candidates that were successfully 
expressed and secreted by CRFK transfected cells had their protein function evaluated.  
 
4.2 Materials and Methods 
Proteins secreted from transfected cells had their oxalate-degrading activity evaluated by 
measuring oxalate content in the media through ion chromatography. Prior to that, 
different amounts of oxalate were added into the cells, in order to check for toxicity and 
to assess any changes in cell growth rates. Based on the results of a MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay, a non-toxic concentration 
of oxalate was determined and added into the samples in order to evaluate oxalate 
degradation over time.  
A MTT assay was performed according to the manufacturer’s instructions (Vybrant MTT 
Cell Proliferation Assay kit – Molecular Probes®) in a 96-well plate and 10,000 cells 
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were plated in each well along with media (100ul). A 0.1 M solution of NaOx (sodium 
oxalate) was prepared, diluted in PBS and filtered to sterilize (0.2 um membrane filter). 
Serial dilutions were made and different concentrations of NaOx, ranging from 50 
umol/L to 100 mmol/L were tested at 24h and 48h. Media only without cells (negative 
control) and cells only without NaOx (positive control) were included in each plate.  
An amount of 5 mmol/L was added on both samples and controls at time of transfection. 
Oxalate and formate ion concentrations of cell supernatant was measured by ion 
chromatography (Department of Geology & Geophysics, University of Minnesota) 24h 
later. Samples were diluted with de-ionized water and analyzed on a Dionex ICS-2000 
ion chromatography system consisting of an AS19 analytical column, ASRS 300 
suppressor, AS40 autosampler, and integrated dual piston pump and conductivity 
detector. The eluant was generated by Reagent Free eluant generator system (Dionex, 
Sunnyvale, CA), which produced a variable concentration KOH eluant, regulated by 
Chromeleon control software. The control program used a comprehensive anion elution 
scheme.  
 
4.3 Results 
The results of MTT assay showed that at both time points there was a decrease in cell 
viability above 5 mM NaOx (Figure 14). Therefore, the following experiments were 
carried with 5 mM NaOx in the culture media. 
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Figure 14. Results of MTT assay – 24h and 48h. 
 
To confirm that transfected cells were expressing a functional oxalate-degrading enzyme, 
cell culture media were supplemented with NaOx and both oxalate and formate 
concentrations were evaluated 24 hours later. Although results did not show a difference 
in oxalate levels between transfected cells and controls (Figure 15), formate levels 
confirmed enzyme activity and also revealed cellular oxalate production and metabolism 
in samples that were not oxalate-supplemented (Figure 16).  
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Figure 15. Ion chromatography results showing oxalate concentration among samples and controls. 
 
 
 
Figure 16. Ion chromatography results showing formate accumulation among samples and controls. 
 
4.4 Discussion 
The MTT assay is based on the conversion of MTT into formazan by living cells, which 
corresponds to the mitochondrial activity. In most cell populations, the total 
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mitochondrial activity is directly related to the number of viable cells. Therefore, this 
assay is broadly used to measure the cytotoxic effects of drugs and other chemical 
compounds utilized on cell lines in vitro. In this study, the addition of NaOx was only 
toxic to the cells on concentrations greater than 10 mmol/L, with no difference after 24 or 
48 hours. Based on these results, an amount of 5mmol/L NaOx was added into samples 
and controls to be further compared by ion chromatography after 24 hours.   
Ion chromatography provides high sensitivity and low detection limits (oxalate: 0.1 
umol/L or 0.01 ug/ml – 1x dilution). Additionally, it is the standard method for 
quantifying oxalate, is relatively rapid, and requires no sample pretreatment other than 
dilution. Nevertheless, analysis of ion chromatography results revealed that recombinant 
OXDC, both bacterial and fungal, did not decrease the oxalate concentration in media 
compared to negative control GFP-transfected cells supplemented with the same 
concentration of NaOx. These results suggest that an excessive amount of oxalate might 
have been added to the cells and we were not able to detect any oxalate-degrading 
activity.  
Since formate is the direct product of oxalate degradation by OXDC, its accumulation 
was also determined instead of oxalate disappearance for evidence of enzymatic activity 
(51). It was the first time ever reported that formate levels were used to evaluate OXDC 
activity. Results clearly showed that untransfected CRFK cells or GFP-transfected cells, 
supplemented or not with NaOx, did not produce any formate, whereas recombinant 
OXDC-transfected cells showed formate production. These results also confirmed our 
suspicion that cells basally produce a certain amount of oxalate – resulted of cell 
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metabolism, since OXDC-transfected cells and not NaOx supplemented, showed a certain 
amount of formate levels.  
Finally, decreasing pH of the culture medium and/or adding oxalate to the cultures 
induces OXDC expression in many fungi and B. subtilis (36, 40, 41, 42). Regardless of 
the species of origin, OXDC requires oxygen for catalytic turnover, has optimal activity 
at acidic pH, is specific for oxalate as substrate, and contains a manganese (Mn) ion 
binding sequence, although it is not known if the Mn-binding sites participate in oxalate 
metabolism or in substrate recognition.  In addition, OXDC was expressed in a foreign, 
mammalian environment.  It is possible that post-translational processing or other 
processing functions in CRFK cells caused a reduction or loss of enzymatic activity. 
In summary, further studies are needed in order to optimize enzymatic activity and to 
further characterize enzymatic activity. This result demonstrates the feasibility of a 
promising therapy and prevention tool against CaOx stones. 
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Chapter 5 – General discussion and conclusion 
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5.1 General Discussion 
Accumulation of oxalate can lead to development and recurrence of CaOx urolithiasis. 
Treatment options for these patients are limited and do not provide a long term solution, 
hence new therapeutic approaches are still needed. We asked in this study, whether 
overexpression of OXDC from fungal and bacterial species can decrease the amount of 
oxalate in a mammalian cell culture system, as an in vitro model. We isolated the OXDC 
gene and studied its expression in a heterologous system, optimizing transfection 
methods and protein secretion. This is the first attempt ever reported to express an 
oxalate-degrading enzyme OXDC into a mammalian cell line. This study provides 
evidence that recombinant OXDC can be expressed, secreted and active in eukaryotic 
cells, which is an important step towards gene therapy approach for hyperoxaluria. 
However, further studies are needed, in order to optimize its activity. 
 
5.2 Conclusion 
A successful outcome is expected to directly benefit companion animals that suffer 
recurrent CaOx stone attacks that are refractory to current therapies and, after further 
refinement, gene therapy may become a front-line option. Additionally, this study will 
trigger additional research focused on determining methods of gene transfer, identifying 
effective and safe delivery routes, prolonging transgene expression and overcoming 
vector-mediated innate immune responses. This is a completely novel and promising 
approach that has potential for high impact on animal and human health. 
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